Unrescetable Hepatocellular Carcinoma
2 clinical trials · Condition
◉ Watch Unrescetable Hepatocellular Carcinoma
| Record | Firm | Date |
|---|---|---|
| HAIC Combined With Cadonilimab and Bevacizumab as First-line Therapy in Unresectable Hepatocellular Carcinoma (NCT05821361) | Tianjin Medical University Cancer Institute and Hospital | 2023-08-01 |
| HAIC Combined With Durvalumab, Tremelimumab and Bevacizumab as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma (NCT05864755) | Tianjin Medical University Cancer Institute and Hospital | 2023-06-20 |
Track Unrescetable Hepatocellular Carcinoma automatically
Every clearance here is in the API, with alerts when new ones post.